CRISPR Therapeutics Revenue and Competitors

Claim your profile

Boston, MA USA

Location

$127M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • CRISPR Therapeutics's estimated annual revenue is currently $92.1M per year.(i)
  • CRISPR Therapeutics received $113.8M in venture funding in January 2018.
  • CRISPR Therapeutics's estimated revenue per employee is $140,780
  • CRISPR Therapeutics's total funding is $127M.

Employee Data

  • CRISPR Therapeutics has 654 Employees.(i)
  • CRISPR Therapeutics grew their employee count by 12% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4280M123836%$28M$63.3B
#2
$1.5M17-6%N/AN/A
#3
$434.8M353827%$2B$2.7B

CRISPR Therapeutics is a leading gene-editing company focused on the development of transformative medicines using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR/Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. Our multi-disciplinary team of world-class researchers and drug developers is working to translate this technology into breakthrough human therapeutics in a number of serious diseases. Our lead programs in beta-thalassemia and sickle cell disease have advanced to IND/CTA-enabling studies with a CTA filing planned by the end of 2017, and we are advancing additional programs in ex vivo and in vivo disease areas. In addition to our fully-owned programs, our strategic collaborations with Bayer AG and Vertex Pharmaceuticals expand our portfolio and enable us with unique capabilities. Through our private financings, partnerships, and IPO we have raised >$400M to fund and accelerate our portfolio. We have licensed the foundational CRISPR/Cas9 patent estate for human therapeutic use from our scientific founder, Dr. Emmanuelle Charpentier, who co-invented the application of CRISPR/Cas9 for gene editing. Our company is headquartered in Zug, Switzerland with R&D operations in Cambridge, Massachusetts, USA and some business operations in London, United Kingdom.

keywords:N/A

$127M

Total Funding

654

Number of Employees

$92.1M

Revenue (est)

12%

Employee Growth %

N/A

Valuation

N/A

Accelerator

CRISPR Therapeutics News

2022-04-19 - CRISPR (CRSP) to Report Q1 Earnings: What's in the Cards?

In the last reported quarter, CRISPR Therapeutics witnessed a negative earnings surprise of 5.8%. CRISPR Therapeutics AG Price and EPS Surprise.

2022-04-19 - CRISPR Therapeutics AG (CRSP) Gains As Market Dips: What You Should Know

CRISPR Therapeutics AG is currently a Zacks Rank #4 (Sell). The Medical - Biomedical and Genetics industry is part of the Medical sector. This...

2022-04-13 - CRISPR Therapeutics Proposes New Appointment to the ...

CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its...

2020-12-29 - Grants for companies fighting HIV, neurodegenerative diseases and drug resistance

CRISPR Therapeutics received a grant from the Bill & Melinda Gates Foundation to research in vivo gene editing therapies for the treatment of HIV. The grant builds upon CRISPR Therapeutics’ proprietary CRISPR/Cas9 gene editing technology and expertise in editing hematopoietic stem cells and cont ...

2020-12-16 - Out of CRISPR pi­o­neer David Li­u's lab comes a small mol­e­cule play tar­get­ing ex­osites — and it's raised a mod­est $25M to push to­ward clin­ic

David Liu may be best known as a CRISPR trail­blaz­er be­hind Ed­i­tas Med­i­cine, Beam Ther­a­peu­tics and Prime Med­i­cine. But more than six years ago, he worked with a stu­dent from his Har­vard lab and then-col­league Alan Saghatelian on a much dif­fer­ent project: de­vel­op­ing a small mol ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$103.4M66743%N/A
#2
$105.7M682358%N/A
#3
$177.4M704N/AN/A
#4
$86.8M70455%$775M
#5
$101.7M712-7%N/A

CRISPR Therapeutics Funding

DateAmountRoundLead InvestorsReference
2018-01-04$115.0MUndisclosedGoldman Sachs & Co. LLCArticle
2018-01-08$113.8MUndisclosedGoldman Sachs & Co. LLCArticle